[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344286-105":59,"doc-detail-344286-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","expanding-the-clinical-utility-of-liquid-biopsy-by-using-liquid-transcriptome-and-artificial-intelligence","Expanding the clinical utility of liquid biopsy by using liquid transcriptome and artificial intelligence","","Most liquid biopsy use relies on analyzing circulating cell-free DNA (cfDNA), while evidence for cell-free RNA (cfRNA) remains limited. Low cfRNA abundance and dilution from multiple tissues hinder liquid transcriptome analysis. This study evaluates artificial intelligence to normalize cancer-specific cfRNA and use liquid transcriptomic profiles for diagnosis. Hybrid-capture next generation sequencing generated cfRNA data from 1009 blood samples.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/expanding-the-clinical-utility-of-liquid-biopsy-by-using-liquid-transcriptome-and-artificial-intelligence/344286/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/expanding-the-clinical-utility-of-liquid-biopsy-by-using-liquid-transcriptome-and-artificial-intelligence/344286.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is liquid transcriptome analysis harder than cfDNA in liquid biopsy?","Question",{"text":113,"@type":114},"cfRNA levels in circulation are low, and RNA from various tissues can dilute tumor-derived signals, complicating interpretation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the study use artificial intelligence in cfRNA-based diagnosis?",{"text":118,"@type":114},"It applies AI to normalize cancer-specific cfRNA transcriptomic patterns so that liquid transcriptome data can predict diagnosis across sample groups.",{"name":120,"@type":111,"acceptedAnswer":121},"What sequencing method generated the cfRNA data for model training and testing?",{"text":122,"@type":114},"Hybrid capture next generation sequencing (NGS) was used to generate cfRNA transcriptomic data from 1009 peripheral blood samples.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344286,1790181740,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","JLB 6 (2024) 100270  \nContents lists available at ScienceDirect  \nThe Journal of Liquid Biopsy  \njournal [homepage:](homepage: www.sciencedirect.com/journal/the-journal-of-liquid-biopsy)[ www.sciencedirect.com/journal/the-journal-of-liquid-biopsy](homepage: www.sciencedirect.com/journal/the-journal-of-liquid-biopsy)  \n| Expanding the clinical utility of liquid biopsy by using liquid transcriptome   and artificial intelligence\u003Cbr>Maher Albitara,*, Ahmad Charifaa, Sally Agersborg a, Andrew Pecorab, Andrew Ip b, Andre Goyb\u003Cbr>a Genomic Testing Cooperative, Lake Forest, CA, USA b John Theurer Cancer Center, Hackensack, NJ, USA |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Liquid biopsy\u003Cbr>cell-free DNA (cfDNA)\u003Cbr>cell-free RNA (cfRNA) Cancer diagnosis\u003Cbr>Next generation sequencing Artificial intelligence (AI) |  | Most of the current utilization of liquid biopsy (LBx) is based on analyzing cell-free DNA(cfDNA). There is limited data on using cell-free RNA (cfRNA) levels (liquid transcriptome) in LBx. The major hurdles for using liquid transcriptome is its low level in circulation and the dilutional effects of various tissues that may pour their RNA into circulation. We explored the potential of using artificial intelligence (AI) to normalize the cancer-specific cfRNA and to enable liquid transcriptome to predict diagnosis. cfRNA transcriptomic data from 1009 peripheral blood samples was generated by hybrid capture next generation sequencing (NGS). Using two-thirds of samples for training and one third for testing, we demonstrate that AI is able to distinguish between normal control (N = 368) and patients with solid tumors (N = 404) with AUC = 0.820 (95 % CI: 0.760–0.879), patients with myeloid neoplasms (N = 99) with AUC = 0.858 (95 % CI: 0.793–0.924) and patients with lymphoid neoplasms (N = 128) with AUC = 0.788 (95 % CI: 0.687–0.888). Specific diagnosis was also possible when patients with lung, breast, colorectal, and myelodysplastic subgroups were tested. This data suggests that liquid transcriptomics when used with AI has the potential of transforming “liquid biopsy” to “true” biopsy, replacing the need for tissue biopsy. |\n\n1. Introduction  \nLiquid biopsy (LBx) has become an essential test for the diagnosis and monitoring of patients with various types of cancer [1–4]. Clinical applications of LBx are growing rapidly. LBx was initially established for hard-to-biopsy patients due to the location of the cancer or due to the presence of significant co-morbidity. Currently LBx is used for early detection or confirmation of the presence of cancer, detecting the presence of actionable alterations, predicting response or resistance to therapy as well as prognosis and survival after immunotherapy or targeted therapy [5–8]. Most of current LBx testing is based on analyzing circulating cell-free DNA (cfDNA). This includes mainly next generation sequencing (NGS), methylation analysis, and fragmentomic analysis [9–11]. However, the utilizing of circulating cell-free RNA (cfRNA) is emerging as a reliable approach [12]. LBx that combines the analysis of cfDNA with cfRNA provides more comprehensive evaluation of molecular abnormalities [12]. Higher sensitivity in detected mutations has been reported when cfRNA is used [12]. However, when the mutations  \nlead to early termination of protein synthesis, which is typically associated with RNA instability, RNA is less sensitive than DNA in detecting mutations [12]. cfRNA also improves detection of fusion genes and chromosomal translocation [13]. More importantly, cfRNA sequencing by NGS provides quantitative expression data of genes and opens the door for utilizing this transcriptomic data to better understand the cancer itself as well as the host [14–16]. cfRNA transcriptomic data has the potential to provide information on the immune system, the level of cytokines and chemokines that are generated by the tumor as well as by the host.  \nExcept for rare","cbCaisxWA2XzDekM","https://ap.wps.com/l/cbCaisxWA2XzDekM","pdf",2728875,"English","# Introduction\n## Liquid biopsy applications and cfDNA-based testing\n## Emerging role of cfRNA and liquid transcriptomics\n## Normalization challenges and AI approach","[{\"question\":\"Why is liquid transcriptome analysis harder than cfDNA in liquid biopsy?\",\"answer\":\"cfRNA levels in circulation are low, and RNA from various tissues can dilute tumor-derived signals, complicating interpretation.\"},{\"question\":\"How does the study use artificial intelligence in cfRNA-based diagnosis?\",\"answer\":\"It applies AI to normalize cancer-specific cfRNA transcriptomic patterns so that liquid transcriptome data can predict diagnosis across sample groups.\"},{\"question\":\"What sequencing method generated the cfRNA data for model training and testing?\",\"answer\":\"Hybrid capture next generation sequencing (NGS) was used to generate cfRNA transcriptomic data from 1009 peripheral blood samples.\"}]","Expanding the clinical utility of liquid biopsy by using liquid transcriptome and artificial intelligence | PDF",1790053346,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b7b711e870f3c4c0e0bd7f70077f00d.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d4fc1edb49fd29a2fd29f296184e3fa.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b3f8ed822abb4a3ae4fb925b1a77ed3.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93b6925b4f7dc0ff5f3a809c2dc2dd72.webp",980,1306]